BriaCell Therapeutics Corp (NASDAQ:BCTX) has a beta value of 1.31 and has seen 3.7 million shares traded in the recent trading session. The company, currently valued at $20.27M, closed the recent trade at $2.99 per share which meant it gained $0.11 on the day or 3.82%% during that session. The BCTX stock price is -883.28% off its 52-week high price of $29.40 and 7.02% above the 52-week low of $2.78. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.12 million shares traded. The 3-month trading volume is 1.43 million shares.
BriaCell Therapeutics Corp (NASDAQ:BCTX) trade information
Sporting 3.82%% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BCTX stock price touched $2.99 or saw a rise of 6.85%. Year-to-date, BriaCell Therapeutics Corp shares have moved -84.43%, while the 5-day performance has seen it change -5.38%. Over the past 30 days, the shares of BriaCell Therapeutics Corp (NASDAQ:BCTX) have changed -12.32%. Short interest in the company has seen 0.52 million shares shorted with days to cover at 0.68.
BriaCell Therapeutics Corp (BCTX) estimates and forecasts
The company’s shares have lost -67.64% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 47.85% over the past 5 years. Earnings growth for 2025 is a modest 41.56% while over the next 5 years, the company’s earnings are expected to increase by 31.60%.
BCTX Dividends
BriaCell Therapeutics Corp is expected to release its next earnings report on 2025-Jun-16 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BriaCell Therapeutics Corp (NASDAQ:BCTX)’s Major holders
Insiders own 7.33% of the company shares, while shares held by institutions stand at 10.88% with a share float percentage of 11.74%. Investors are also buoyed by the number of investors in a company, with BriaCell Therapeutics Corp having a total of 18.0 institutions that hold shares in the company.
